ABSTRACT
Paper microfluidics has had a rich history in medical diagnostics owing to their portability, low-cost and capacity for mass manufacture. While nitrocellulose has widespread use in commercial paper-based assays, shortages can become a bottleneck for deployment. Here, we seek to overcome this limitation by enabling swift and efficient production of cellulose-based paper assays with minimal substrate processing via protein engineering. We demonstrate good clinical and lab-based performance for both serological and antigen rapid tests and their compatibility with roll-to-roll mass manufacturing, which validates our proposed workflow for commercialization. © 2021 MicroTAS 2021 - 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences. All rights reserved.